Get started
LYTIX BIOPHARMA ASLYTIX BIOPHARMA ASLYTIX BIOPHARMA AS

LYTIX BIOPHARMA AS

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

LYTIX fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Lytix Biopharma AS engages in the development of novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company was founded by Øystein Rekdal and John Sigurd Mjøen Svendsen in 2003 and is headquartered in Tromso, Norway.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

LYTIX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company